A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend for undiagnosed gastrointestinal discomfort
- 2019-11
- RCT · n = 60
- International Journal of Colorectal Disease 34(11)
- R. J. Soman
- M. Swamy
- PubMed: 31686199
- DOI: 10.1007/s00384-019-03416-w
- High evidence
- Rigorous Journal
Significant improvement in final SODA scores and subscores with SNZ TriBac versus placebo indicates improvement in several symptoms of gastrointestinal discomfort. This multistrain probiotic blend was well tolerated and could be an effective option for treatment of GI discomfort.
- Effect
- Beneficial
- Effect size
- Moderate
- Significant
- Yes